Clinical trial
A Phase 2, Randomized, Multicenter, Double-blind, Vehicle-controlled, Dose-ranging Study to Evaluate the Efficacy and Safety of VB-1953 Topical Gel When Applied Once or Twice Daily for 12 Weeks in Subjects With Moderate to Severe Inflammatory Facial Acne Vulgaris
NCT03900676 is registered in ClinicalTrials.gov with Vyome Therapeutics Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2, Randomized, Multicenter, Double-blind, Vehicle-controlled, Dose-ranging Study to Evaluate the Efficacy and Safety of VB-1953 Topical Gel When Applied Once or Twice Daily for 12 Weeks in Subjects With Moderate to Severe Inflammatory Facial Acne Vulgaris
- Lead sponsor
- Vyome Therapeutics Inc.
- Phase
- Phase 2
- Overall status
- Unknown status
- Start date
- April 9, 2019
- Completion date
- March 31, 2020
- Enrollment
- 480 (estimated)
- Sites
- 12
Conditions
As the registry lists them; a condition with its own page is linked.